Back to User profile » Dr Huafang Li
Papers published by Dr Huafang Li:
A Random Forest Model for Predicting Social Functional Improvement in Chinese Patients with Schizophrenia After 3 Months of Atypical Antipsychotic Monopharmacy: A Cohort Study
Li Y, Zhang L, Zhang Y, Wen H, Huang J, Shen Y, Li H
Neuropsychiatric Disease and Treatment 2021, 17:847-857
Published Date: 19 March 2021
Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study
Weng JJ, Wang LH, Zhu H, Xu WR, Wei YM, Wang ZY, Yu WJ, Li HF
Neuropsychiatric Disease and Treatment 2019, 15:2195-2203
Published Date: 7 August 2019
Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
Li H, Li Y, Feng Y, Zhuo J, Turkoz I, Mathews M, Tan W
Neuropsychiatric Disease and Treatment 2018, 14:1107-1117
Published Date: 26 April 2018
Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
Zhang H, Li H, Liu Y, Wu C, Wu Q, Nuamah I, Shi J, Xie S, Wang G, Gopal S
Neuropsychiatric Disease and Treatment 2016, 12:69-77
Published Date: 8 January 2016
Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
Li HF, Turkoz I, Zhang F
Neuropsychiatric Disease and Treatment 2016, 12:15-24
Published Date: 21 December 2015